Review

*Author for correspondence:

https://orcid.org/0000-0003-0399-4672

Hematology & Oncology Department, Faculty of Medicine, Saint Joseph University, Beirut, Lebanon

Search for more papers by this author

Hampig Raphael Kourie

Hematology & Oncology Department, Faculty of Medicine, Saint Joseph University, Beirut, Lebanon

Search for more papers by this author

Published Online:3 Nov 2021https://doi.org/10.2217/pgs-2021-0119

View article

Abstract

Poly-(ADP-ribose) polymerase (PARP) inhibitors act in cells with defects in homologous recombination DNA repair (HRR) caused by genomic aberrations such as BRCA mutations. This phenomenon called synthetic lethality is known now to be more common in prostate cancer than previously thought. Olaparib and rucaparib, two PARP inhibitors, were successfully tested in clinical trials for HRR-deficient metastatic castration-resistant prostate cancer. They received a breakthrough US FDA approval in HRR altered metastatic castration-resistant prostate cancer in May 2020. Consequently, the combination of PARP inhibitors with other agents such as androgen receptor pathway inhibitors, immune checkpoint inhibitors or DNA damage inducing chemotherapy are being currently largely studied. In our review, we aim to summarize the key PARP inhibitors published and ongoing trials in prostate cancer.

Keywords:

References

1. Hoffman RM. Clinical practice. Screening for prostate cancer. N. Engl. J. Med. 365(21), 2013–2019 (2011).
Medline CASGoogle Scholar
2. Rawla P. Epidemiology of prostate cancer. World J Oncol. 10(2), 63–89 (2019).
Medline CASGoogle Scholar
3. Prostate Cancer Treatment (PDQ^®)–Patient Version - National Cancer Institute [Internet] (2020). https://www.cancer.gov/types/prostate/patient/prostate-treatment-pdq
Google Scholar
4. Prostate cancer - types of treatment [Internet] (2012). https://www.cancer.net/cancer-types/prostate-cancer/types-treatment
Google Scholar
5. Common treatments for advanced prostate cancer [Internet]. https://www.webmd.com/prostate-cancer/prostate-cancer-advanced-treatments
Google Scholar
6. de Bono JS, Logothetis CJ, Molina A et al. Abiraterone and increased survival in metastatic prostate cancer. N. Engl. J. Med. 364(21), 1995–2005 (2011).
Medline CASGoogle Scholar
7. Ryan CJ, Smith MR, de Bono JS et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N. Engl. J. Med. 368(2), 138–148 (2013).
Medline CASGoogle Scholar
8. Beer TM, Armstrong AJ, Rathkopf DE et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N. Engl. J. Med. 371(5), 424–433 (2014).
MedlineGoogle Scholar
9. Scher HI, Fizazi K, Saad F et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N. Engl. J. Med. 367(13), 1187–1197 (2012).
Medline CASGoogle Scholar
10. Moore K, Colombo N, Scambia G et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N. Engl. J. Med. 379(26), 2495–2505 (2018).
Medline CASGoogle Scholar
11. Robinson D, Van Allen EM, Wu Y-M et al. Integrative clinical genomics of advanced prostate cancer. Cell 161(5), 1215–1228 (2015).
Medline CASGoogle Scholar
12. D'Andrea AD. Mechanisms of PARP inhibitor sensitivity and resistance. DNA Repair (Amst.) 71, 172–176 (2018).
MedlineGoogle Scholar
13. Hoppe MM, Sundar R, Tan DSP, Jeyasekharan AD. Biomarkers for homologous recombination deficiency in cancer. J. Natl Cancer Inst. 110(7), 704–713 (2018).
MedlineGoogle Scholar
14. Ratta R, Guida A, Scotté F et al. PARP inhibitors as a new therapeutic option in metastatic prostate cancer: a systematic review. Prostate Cancer Prostatic Dis. 23(4), 549–560 (2020).
Medline CASGoogle Scholar
15. Haddad G, Saadé MC, Eid R, Haddad FG, Kourie HR. PARP inhibitors: a tsunami of indications in different malignancies. Pharmacogenomics 21(3), 221–230 (2020).
CASGoogle Scholar
16. Brönimann S, Lemberger U, Bruchbacher A, Shariat SF, Hassler MR. Poly(ADP-ribose) polymerase inhibitors in prostate and urothelial cancer. Curr Opin Urol. 30(4), 519–526 (2020).
MedlineGoogle Scholar
17. FDA. Research C for DE and FDA approves olaparib for HRR gene-mutated metastatic castration-resistant prostate cancer (2021). https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer
Google Scholar
18. FDA. Research C for DE and FDA grants accelerated approval to rucaparib for BRCA-mutated metastatic castration-resistant prostate cancer. 2021). https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-rucaparib-brca-mutated-metastatic-castration-resistant-prostate
Google Scholar
19. Mateo J, Carreira S, Sandhu S et al. DNA-repair defects and olaparib in metastatic prostate cancer. N. Engl. J. Med. 373(18), 1697–1708 (2015).
Medline CASGoogle Scholar
20. Mateo J, Porta N, Bianchini D et al. Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, Phase 2 trial. Lancet Oncol. 21(1), 162–174 (2020).
Medline CASGoogle Scholar
21. de Bono J, Mateo J, Fizazi K et al. Olaparib for metastatic castration-resistant prostate cancer. N. Engl. J. Med. 382(22), 2091–2102 (2020).
Medline CASGoogle Scholar
22. Abida W, Campbell D, Patnaik A et al. Preliminary results from the TRITON2 study of rucaparib in patients (pts) with DNA damage repair (DDR)-deficient metastatic castration-resistant prostate cancer (mCRPC): updated analyses. Ann. Oncol. 30, v327–v328 (2019).
Google Scholar
23. Smith MR, Sandhu SK, Kelly WK et al. Pre-specified interim analysis of GALAHAD: a Phase II study of niraparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD). Ann. Oncol. 30, v884–v885 (2019).
MedlineGoogle Scholar
24. Mehanna J, Haddad FG, Eid R, Lambertini M, Kourie HR. Triple-negative breast cancer: current perspective on the evolving therapeutic landscape. Int. J. Womens Health 11, 431–437 (2019).
Medline CASGoogle Scholar
25. de Bono JS, Mehra N, Scagliotti GV et al. Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, Phase 2 trial. Lancet Oncol. S1470-2045(21)0037 6–4 (2021).
MedlineGoogle Scholar
26. Clarke N, Wiechno P, Alekseev B et al. Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, Phase 2 trial. Lancet Oncol. 19(7), 975–986 (2018).
Medline CASGoogle Scholar
27. TALAPRO-2: a two-part, placebo-controlled Phase III study of talazoparib (TALA) with enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC). J. Clin. Oncol. [Internet]. https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.7_suppl.TPS337
Google Scholar
28. Targeting androgen receptor and DNA repair in metastatic castration-resistant prostate cancer: Results From NCI 9012 - PubMed [Internet]. https://pubmed.ncbi.nlm.nih.gov/29261439/
Google Scholar
29. Fay AP, Antonarakis ES. Blocking the PD-1/PD-L1 axis in advanced prostate cancer: are we moving in the right direction? Ann. Transl. Med. 7(Suppl. 1), S7 (2019).
Medline CASGoogle Scholar
30. Arija JAA, Yu EY, Piulats JM et al. 621P Pembrolizumab (pembro) plus olaparib in patients (pts) with docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 Cohort A update. Ann. Oncol. 31, S513–S514 (2020).
Google Scholar
31. Hussain M, Carducci MA, Slovin S et al. Targeting DNA repair with combination veliparib (ABT-888) and temozolomide in patients with metastatic castration-resistant prostate cancer. Invest. New Drugs 32(5), 904–912 (2014).
Medline CASGoogle Scholar
32. Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin. Cancer Res. 3(1), 81–85 (1997).
Medline CASGoogle Scholar
33. Wang X, Yin L, Rao P et al. Targeted treatment of prostate cancer. J. Cell. Biochem. 102(3), 571–579 (2007).
Medline CASGoogle Scholar
34. Santoni M, Scarpelli M, Mazzucchelli R et al. Targeting prostate-specific membrane antigen for personalized therapies in prostate cancer: morphologic and molecular backgrounds and future promises. J. Biol. Regul. Homeost. Agents 28(4), 555–563 (2014).
Medline CASGoogle Scholar
35. Abida W, Patnaik A, Campbell D et al. Rucaparib in men with metastatic castration-resistant prostate cancer harboring a BRCA1 or BRCA2 gene alteration. J. Clin. Oncol. 38(32), 3763–3772 (2020).
Medline CASGoogle Scholar
36. Lim JSJ, Tan DSP. Understanding resistance mechanisms and expanding the therapeutic utility of PARP inhibitors. Cancers (Basel) 9(8), 109 (2017).
Google Scholar
37. Edwards SL, Brough R, Lord CJ et al. Resistance to therapy caused by intragenic deletion in BRCA2. Nature 451(7182), 1111–1115 (2008).
Medline CASGoogle Scholar
38. Lawlor D, Martin P, Busschots S et al. PARP Inhibitors as P-glyoprotein substrates. J. Pharm. Sci. 103(6), 1913–1920 (2014).
Medline CASGoogle Scholar
39. Jaspers JE, Kersbergen A, Boon U et al. Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors. Cancer Discov. 3(1), 68–81 (2013).
Medline CASGoogle Scholar
40. Cao L, Xu X, Bunting SF et al. A selective requirement for 53BP1 in the biological response to genomic instability induced by Brca1 deficiency. Mol. Cell. 35(4), 534–541 (2009).
Medline CASGoogle Scholar
41. Bunting SF, Callén E, Kozak ML et al. BRCA1 functions independently of homologous recombination in DNA interstrand crosslink repair. Mol Cell. 46(2), 125–135 (2012).
Medline CASGoogle Scholar

Vol. 22, No. 18

Metrics

Downloaded 320 times

History

Received 7 September 2021

Accepted 18 October 2021

Published online 3 November 2021

Published in print December 2021

Information

Keywords

Author contributions

HR Kourie certifies that each co-author listed above participated sufficiently in the work to take responsibility for the content, and that all those who qualify are listed. All authors presented substantial contributions to the conception or design of the work, or the acquisition, analysis or interpretation of data for the work; drafted the work or revised it critically for important intellectual content; gave final approval of the version to be published; and agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Financial & competing interests disclosure

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.

Data sharing statement

Searching for ongoing trials studying PARP inhibitors in prostate cancer either in monotherapy or in combination with other treatment modalities was done using the trial registry clinicaltrials.gov.

PDF download

Poly(ADP-ribose) polymerase inhibitors in prostate cancer: a cornerstone in precision oncology

Abstract

References